{"id":"dyanavel-xr","safety":{"commonSideEffects":[{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Irritability"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":{"setId":"ae304b29-0b40-40ec-ad0d-76b742d4a9b9","title":"DYANAVEL XR (AMPHETAMINE) SUSPENSION, EXTENDED RELEASE DYANAVEL XR (AMPHETAMINE) TABLET, EXTENDED RELEASE [NEXTWAVE PHARMACEUTICALS, INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amphetamine is a sympathomimetic amine that acts as a central nervous system stimulant by promoting the release of catecholamines (dopamine and norepinephrine) from presynaptic neurons and inhibiting their reuptake. The extended-release formulation provides sustained therapeutic levels throughout the day, improving focus, attention, and impulse control in patients with ADHD. This mechanism helps normalize neurotransmitter activity in brain regions responsible for executive function and behavioral control.","oneSentence":"Dyanavel XR is an extended-release liquid formulation of amphetamine that increases the release of dopamine and norepinephrine in the central nervous system to improve attention and reduce hyperactivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:49.940Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"}]},"trialDetails":[{"nctId":"NCT06853665","phase":"PHASE4","title":"The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine","status":"RECRUITING","sponsor":"Gagan Joshi","startDate":"2026-02-01","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Autism, Autism Spectrum Disorder","enrollment":196},{"nctId":"NCT07314333","phase":"PHASE1","title":"A Trial to Assess How Centanafadine Interacts With Stimulants in the Body","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-02-05","conditions":"ADHD","enrollment":42},{"nctId":"NCT05916339","phase":"PHASE4","title":"AWARE: Management of ADHD in Autism Spectrum Disorder","status":"RECRUITING","sponsor":"Daniel Coury","startDate":"2023-10-01","conditions":"ADHD, Autism Spectrum Disorder","enrollment":500},{"nctId":"NCT07169162","phase":"PHASE4","title":"ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder","status":"WITHDRAWN","sponsor":"Aytu BioPharma, Inc.","startDate":"2019-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT05650775","phase":"PHASE1","title":"Biomarkers of ADHD Treatment Response","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2023-02-17","conditions":"ADHD","enrollment":16},{"nctId":"NCT06248229","phase":"PHASE4","title":"A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).","status":"RECRUITING","sponsor":"Rochester Center for Behavioral Medicine","startDate":"2024-09-01","conditions":"Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder","enrollment":50},{"nctId":"NCT02676739","phase":"PHASE2, PHASE3","title":"Adderall XR and Cognitive Impairment in MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarah Morrow","startDate":"2016-05-20","conditions":"Multiple Sclerosis","enrollment":180},{"nctId":"NCT02478788","phase":"PHASE4","title":"Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2015-11","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":153},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":41},{"nctId":"NCT03242772","phase":"PHASE2","title":"Impact of Combined Medication and Behavioral Treatment for ASD & ADHD","status":"TERMINATED","sponsor":"Duke University","startDate":"2018-12-14","conditions":"Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder","enrollment":18},{"nctId":"NCT01986075","phase":"PHASE1, PHASE2","title":"A Sequenced Behavioral and Medication Intervention for Cocaine Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-01","conditions":"Cocaine Dependence","enrollment":145},{"nctId":"NCT04152629","phase":"PHASE4","title":"Real World Evidence of the Efficacy and Safety of FOQUEST","status":"COMPLETED","sponsor":"Purdue Pharma, Canada","startDate":"2019-09-19","conditions":"Attention Deficit-Hyperactivity Disorder","enrollment":257},{"nctId":"NCT01235338","phase":"PHASE1","title":"Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2010-10-28","conditions":"Healthy","enrollment":80},{"nctId":"NCT00746733","phase":"PHASE1","title":"Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC","status":"COMPLETED","sponsor":"Shire","startDate":"2008-09-08","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT00776555","phase":"PHASE1","title":"Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution","status":"TERMINATED","sponsor":"Shire","startDate":"2008-11-21","conditions":"Healthy","enrollment":3},{"nctId":"NCT00506727","phase":"PHASE4","title":"Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD","status":"COMPLETED","sponsor":"Shire","startDate":"2003-08-05","conditions":"ADHD","enrollment":215},{"nctId":"NCT00507065","phase":"PHASE3","title":"Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2003-05-28","conditions":"ADHD","enrollment":329},{"nctId":"NCT00557960","phase":"PHASE3","title":"ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD","status":"COMPLETED","sponsor":"Shire","startDate":"2004-02-25","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":36},{"nctId":"NCT02803229","phase":"PHASE2, PHASE3","title":"Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2016-07","conditions":"Cannabis Use Disorder, Attention-deficit/Hyperactivity Disorder","enrollment":33},{"nctId":"NCT03088267","phase":"PHASE3","title":"Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2017-02-11","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":18},{"nctId":"NCT03610464","phase":"PHASE4","title":"Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2018-05-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":5},{"nctId":"NCT00553319","phase":"PHASE2, PHASE3","title":"Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-12","conditions":"Adult Attention Deficit Hyperactivity Disorder, Cocaine Dependence","enrollment":139},{"nctId":"NCT00421603","phase":"PHASE2","title":"A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-02","conditions":"Cocaine Dependence","enrollment":81},{"nctId":"NCT02210728","phase":"NA","title":"Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder","status":"UNKNOWN","sponsor":"Lily Hechtman","startDate":"2006-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":200},{"nctId":"NCT02788851","phase":"NA","title":"The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-04","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":70},{"nctId":"NCT02566824","phase":"PHASE4","title":"Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2010-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":216},{"nctId":"NCT01478113","phase":"NA","title":"Stimulant Enhancement of Well-Being Therapy for Depression","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2012-02","conditions":"Major Depressive Disorder","enrollment":5},{"nctId":"NCT00393042","phase":"PHASE3","title":"Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2006-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":77},{"nctId":"NCT01133847","phase":"PHASE4","title":"Interventions for Children With Attention and Reading Disorders","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2010-11","conditions":"Attention Deficit Hyperactivity Disorder, Reading Disabilities","enrollment":222},{"nctId":"NCT00069927","phase":"PHASE2","title":"Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression","status":"TERMINATED","sponsor":"University of South Florida","startDate":"2003-08","conditions":"Depression, Neurotoxicity, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":12},{"nctId":"NCT00889915","phase":"PHASE4","title":"Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-04","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":228},{"nctId":"NCT00712699","phase":"NA","title":"Effectiveness of an Extended Release Stimulant Medication in Treating Preschool Children With ADHD","status":"COMPLETED","sponsor":"Baystate Medical Center","startDate":"2008-06","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":27},{"nctId":"NCT00557011","phase":"PHASE2","title":"NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD","status":"COMPLETED","sponsor":"New River Pharmaceuticals","startDate":"2004-09","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dyanavel XR","genericName":"Dyanavel XR","companyName":"Rochester Center for Behavioral Medicine","companyId":"rochester-center-for-behavioral-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dyanavel XR is an extended-release liquid formulation of amphetamine that increases the release of dopamine and norepinephrine in the central nervous system to improve attention and reduce hyperactivity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}